Idiopathic Parkinson Disease Clinical Trial
Official title:
A Naturalistic, Multisite, Observational Study of Rotigotine Transdermal Patch and Other Currently Prescribed Therapies in Patients With Idiopathic Parkinson's Disease
This study will be conducted in an observational multiple-cohort design aimed at acquiring clinical, treatment, health status, and economic data. Patients with Parkinson's disease (PD) will be enrolled.
All patients attending the physician and fulfilling the eligibility criteria are included. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05103618 -
Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA
|
Phase 2 | |
| Completed |
NCT03700684 -
Voice Treatment for Parkinson's Disease
|
N/A | |
| Completed |
NCT04202757 -
Intravenous Plasma Treatment for Parkinson's Disease
|
Early Phase 1 | |
| Completed |
NCT05027620 -
Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology
|
N/A | |
| Completed |
NCT03652363 -
GDNF in ideopathicParkinsons Disease
|
Phase 2 | |
| Recruiting |
NCT02960464 -
tDCS for Treatment of Depression in Parkinson's Disease
|
N/A | |
| Completed |
NCT05699161 -
Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson
|
Phase 1/Phase 2 | |
| Completed |
NCT03944785 -
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
|
||
| Completed |
NCT01227265 -
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
|
Phase 3 | |
| Terminated |
NCT01215227 -
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
|
Phase 3 | |
| Withdrawn |
NCT05832775 -
Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's
|
Phase 1 | |
| Active, not recruiting |
NCT02780895 -
Parkinsonian Brain Repair Using Human Stem Cells
|
Phase 1 | |
| Recruiting |
NCT01860794 -
Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease
|
Phase 1/Phase 2 | |
| Terminated |
NCT02393027 -
Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999
|
Early Phase 1 | |
| Completed |
NCT02373072 -
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
|
Phase 1 | |
| Completed |
NCT02445651 -
Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
|
N/A | |
| Completed |
NCT00437125 -
Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
|
Phase 4 | |
| Completed |
NCT02723396 -
Sleep, Awake & Move - Part I
|
||
| Not yet recruiting |
NCT05471609 -
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
|
Early Phase 1 | |
| Completed |
NCT00160576 -
Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
|
Phase 2 |